Epidemia de influenza del año 2009 en un hospital pediátrico y costos médicos directos en menores de 5 años comparados con el período 2006-2008

Giglio, Norberto; Castellano, Vanesa; Rüttimann, Ricardo; Vidal, Gabriela I.; Gentile, Ángela

doi:10.5546/aap.2012.19

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As this study was derived from a systematic review completed in September 2011, studies published later are not included. Nonetheless, an update of our search strategy in MEDLINE/PubMed covering from September 2011 to September 2012 indicates that, although the scope of settings and interventions has broadened, there are few eligible additional economic evaluations18, 19, 20, 21 and most of the studies are cost analyses 22, 23, 24, 25. We believe that our results are still valid even though these new studies are not included.…”

Section: Discussionmentioning

confidence: 79%

Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters

Praditsitthikorn

Kotirum

Mohara

et al. 2013

Influenza Resp Viruses

View full text Add to dashboard Cite

BackgroundIn our previous systematic review of economic evaluations of pandemic influenza interventions, five model parameters, namely probability of pandemic, duration of pandemic, severity, attack rate, and intervention efficacy, were not only consistently used in all studies but also considered important by authors.ObjectivesBecause these parameters originated from sources of varying quality ranging from experimental studies to expert opinion, this study aims to analyze the variation in values used according to sources of information across studies.MethodsAn analysis of estimated values of key parameters for economic modeling was performed against their different data sources, following the standard hierarchy of evidence.ResultsA lack of good‐quality evidence to estimate pandemic duration, pandemic probability, and mortality reduction from antiviral treatment results in a large variation of values used in economic evaluations. Although there are variations in quality of evidence used for attack rate, basic reproduction number, and reduction in hospitalizations from antiviral treatment, the estimated values do not vary significantly. The use of higher‐quality evidence results in better precision of estimated values compared to lower‐quality sources.ConclusionHierarchies of evidence are a necessary tool to identify appropriate model parameters to populate economic evaluations and should be included in methodological guidelines. Knowledge gaps in some key parameters should be addressed, because if good‐quality evidence is available, future economic evaluations will be more reliable. Some gaps may not be fulfilled by research but consensus among experts to ensure consistency in the use of these assumptions.

show abstract

Section: Discussionmentioning

confidence: 79%

Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters

Praditsitthikorn

Kotirum

Mohara

et al. 2013

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…At a children's hospital in Buenos Aires (Hospital de Niños Ricardo Gutierrez), during 2000-2013, influenza accounted for 7% of all respiratory virus isolations (4). In a pharmaco-economic study at the same institution, estimated annual costs attributable to influenza in children under 5 years old ranged from US$ 250 000 to US$ 350 000 (5). Influenza mortality data are not available for the same period for Argentina.…”

Section: Epidemiology and Burden Of Influenza Argentinamentioning

confidence: 99%

Epidemiology and prevention of influenza in children in Argentina and Brazil

Group¹

2017

Revista Panamericana De Salud Pública

View full text Add to dashboard Cite

A group of influenza experts from Argentina and Brazil got together to discuss the burden of influenza in children, review current vaccine coverage rates in both countries, analyze vaccine effectiveness, and discuss strategies to improve prevention. Active surveillance of respiratory viruses is carried out nationwide in both countries. Years 2014 and 2015 were mild influenza seasons; influenza virus type A/H3N2 prevailed, whereas type B represented less than 30% of isolates. Trivalent inactivated influenza vaccine is included in National Immunization Programs for 1) children 6 months to 2 years old in Argentina; 2) children 6 months to 5 years old in Brazil; and 3) all high-risk individuals. Coverage rates in both countries were about 80% (albeit lower for the second dose). Experts from both countries proposed the following strategies to improve prevention: 1) increase surveillance; 2) assess effectiveness and long-term safety of influenza vaccines; 3) reinforce vaccination programs in order to increase coverage rates; and 4)consider introducing more effective vaccines, such as adjuvanted trivalent vaccines. In Argentina, estimating casefatality rates was also recommended. Other proposed actions included enhancing education of health professionals and the lay community, and better use of communication resources to raise awareness of the burden of influenza and promote vaccine uptake.

show abstract

A systematic review of the social and economic burden of influenza in low- and middle-income countries

Francisco

Donadel

Jit

et al. 2015

Vaccine

112

View full text Add to dashboard Cite

Epidemia de influenza del año 2009 en un hospital pediátrico y costos médicos directos en menores de 5 años comparados con el período 2006-2008

Cited by 3 publications

References 16 publications

Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters

Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters

Epidemiology and prevention of influenza in children in Argentina and Brazil

A systematic review of the social and economic burden of influenza in low- and middle-income countries

Contact Info

Product

Resources

About